Category: Diabetes

Introduction and Objective: We evaluated the effectiveness of CGM versus BGM in the pragmatic management of T2D on insulin in primary care, in a large randomized controlled trial in the upper Midwest.Methods: This two-arm trial was cluster-randomized based on primary care clinic attendance: (BGM 25 clinics) or CGM (25 clinics). We recruited 360 adults with […]

Introduction and Objective: Monitoring of beta cell function in those with preclinical T1D relies on serial frequently sampled oral glucose tolerance tests (OGTT), which poses major challenges given the practical burden and expense of this test. Herein, we validated a fully CGM-derived disposition index (DICGM) – a proxy of beta cell function -computed against the […]

Introduction and Objective: Basal insulin dose titration is traditionally guided by self-monitored FBG and documented hypoglycemic events. This retrospective analysis evaluated CGM-derived indicators for use in dose titration of weekly basal insulin in insulin-naïve adults with T2D.Methods: CGM indicators of FBG were calculated from 3730 weekly insulin dose decisions, while hypoglycemic events were assessed using […]

Introduction and Objective: Despite the widespread digitalization of diabetes care, significant disparities remain in individuals’ skills and confidence using digital health tools. We consulted with patients and clinicians to develop a program, called ADDS (Assistance with Diabetes Digital health Skills), to improve the digital health literacy of adults with type 2 diabetes (T2D) and explored […]

Introduction and Objective: We previously (BMJ Open Diab: e004199, 2024) showed that a 10-day weight-maintaining ketogenic diet in individuals with type 2 diabetes did not change OGTT responses or insulin sensitivity (two-step euglycemic clamp) but increased insulin secretion.To examine the effect of the 10-day weight-maintaining ketogenic or standard diet on fasting plasma glucagon and OGTT […]

Introduction and Objective: Despite being a major contributor to reduced life expectancy in type 1 diabetes (T1D), cardiovascular disease (CVD) and T1D-associated cardiomyopathy remain poorly understood. Insulin-like growth factor binding protein-7 (IGFBP7), a member of the IGFBPs, was found elevated in serum of patients with heart failure and kidney disease. Clinical studies in patients with […]

Introduction and Objective: Obesity and prediabetes are characterized by abnormal glucagon response to glucose and amino acids (AA). Elevated AA concentrations, seen in these states, are associated with increased risk of type 2 diabetes. The relative contributions of AA, glucose and insulin to glucagon secretion is unknown.Methods: Lean (BMI: 23 ± 0.5 kg/m2, n = […]

Introduction and Objective: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are widely used for type 2 diabetes and reduce hospitalization and cardiovascular death in heart failure with reduced ejection fraction (HFrEF). Ventricular arrhythmias are a major cause of death in HFrEF, but the effect of SGLT2i on arrhythmia risk remains unclear. This systematic review and meta-analysis evaluated whether […]

Introduction and Objective: Proteomics can provide insight into mechanisms linking diabetes to dementia risk. We identified plasma central nervous system (CNS) proteins associated with incident dementia in older adults with diabetes.Methods: We conducted a prospective cohort study of 487 ARIC Study participants with diabetes (age 58-84y, 47% women, 34% Black) in 2005-06. We quantified the […]

Introduction and Objective: Glucagon-like peptide 1 (GLP1) receptor agonists such as semaglutide have made medical weight loss possible, but for many the continued treatment necessary to maintain the weight loss is not sustainable. Reasons include gastrointestinal side effects, loss of lean/muscle mass, need for injections, and high cost. This results in half of the people […]